UNSPSC 51373418: Caffeine/codeine/menthol/pheniramine/phenylephrine/sodium/sodium

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.

UNSPSC 51373418 Caffeine/codeine/menthol/pheniramine/phenylephrine/sodium/sodium, a Commodity code, encompasses pharmaceutical products and over-the-counter medications that state and local governments procure for public health initiatives, community health programs, and emergency response. Recent solicitations show state and local buyers acquiring naloxone kits for opioid-overdose response, safe drug deactivation systems, and generic multi-source pharmaceuticals with specific National Drug Codes for distribution across government facilities. Issuing bodies include county health departments and state cooperative purchasing alliances coordinating multi-jurisdictional pharmaceutical procurement; Seminole County, Florida and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) appear as recent active buyers in this space.

Recent activity spans Florida and Minnesota, with MMCAP's RFP extending cooperative purchasing reach to Oregon and other member states. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its Community Health Building in Sanford, with responses due July 26, 2026. The Minnesota Department of Administration's MMCAP issued RFP S1070000015802 on January 20, 2026, to establish multiple contracts for generic pharmaceuticals and OTC products through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson), with proposals due March 26, 2026, and awarded vendors effective July 1, 2026. Both solicitations require E-Verify compliance, comprehensive insurance coverage, and FDA compliance; MMCAP additionally requires current Good Manufacturing Practices (cGMP) certification and Drug Supply Chain Security Act (DSCSA) compliance, with pricing weighted at 75 percent of the evaluation.